Ceramide 1-phosphate is a Direct Activator of Cytosolic Phospholipase A2
Overview
Authors
Affiliations
Recently, we demonstrated that ceramide kinase, and its product, ceramide 1-phosphate (Cer-1-P), were mediators of arachidonic acid released in cells in response to interleukin-1beta and calcium ionophore (Pettus, B. J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y. A., and Chalfant, C. E. (2003) J. Biol. Chem. 278, 38206-38213). In this study, we demonstrate that down-regulation of cytosolic phospholipase A(2) (cPLA(2)) using RNA interference technology abolished the ability of Cer-1-P to induce arachidonic acid release in A549 cells, demonstrating that cPLA(2) is the key phospholipase A(2) downstream of Cer-1-P. Treatment of A549 cells with Cer-1-P (2.5 microm) induced the translocation of full-length cPLA(2) from the cytosol to the Golgi apparatus/perinuclear regions, which are known sites of translocation in response to agonists. Cer-1-P also induced the translocation of the CaLB/C2 domain of cPLA(2) in the same manner, suggesting that this domain is responsive to Cer-1-P either directly or indirectly. In vitro studies were then conducted to distinguish these two possibilities. In vitro binding studies disclosed that Cer-1-P interacts directly with full-length cPLA(2) and with the CaLB domain in a calcium- and lipid-specific manner with a K(Ca) of 1.54 microm. Furthermore, Cer-1-P induced a calcium-dependent increase in cPLA(2) enzymatic activity as well as lowering the EC(50) of calcium for the enzyme from 191 to 31 nm. This study identifies Cer-1-P as an anionic lipid that translocates and directly activates cPLA(2), demonstrating a role for this bioactive lipid in the mediation of inflammatory responses.
Xie X, Macknight H, Lu A, Chalfant C Mol Ther Nucleic Acids. 2025; 36(1):102412.
PMID: 39807365 PMC: 11728077. DOI: 10.1016/j.omtn.2024.102412.
Hengst J, Ruiz-Velasco V, Raup-Konsavage W, Vrana K, Yun J Cancers (Basel). 2024; 16(23).
PMID: 39682160 PMC: 11639868. DOI: 10.3390/cancers16233973.
Wu Q, Liu K, Hou R, Wu X, Ruan X, Wang M Drug Des Devel Ther. 2024; 18:5087-5108.
PMID: 39554759 PMC: 11568858. DOI: 10.2147/DDDT.S476494.
Farooqui A, Farooqui T Int J Mol Sci. 2024; 25(19).
PMID: 39409002 PMC: 11476704. DOI: 10.3390/ijms251910672.
Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?.
Foran D, Antoniades C, Akoumianakis I Nutrients. 2024; 16(19).
PMID: 39408263 PMC: 11478599. DOI: 10.3390/nu16193296.